BioLens tracks the moments that actually move biotech stocks — FDA decision dates, trial readouts, earnings — and puts them next to live prices and your own notes. It's free, there's no account, and your watchlist stays in your browser unless you turn on sync.
Nothing to install and nothing to sign up for. Open the tracker and add your first ticker:
Not sure where to start? The Trending today panel shows biotech movers; the + on any of those adds it in one click. If no catalyst is found yet, you can still track the name as Watching and rescan later — companies announce dates all the time.
A few keys save a trip to the mouse: a add a stock, / jump to the filter box, r refresh prices, t switch between list and timeline, p open your positions, g open the portfolio chart. They're ignored while you're typing in a field.
Tickers are grouped by how close their next catalyst is, and each card carries a coloured edge:
The circle on each card counts down to that ticker's nearest catalyst — the number inside is days remaining, and the arc fills as the date approaches.
List is the grouped view above. Timeline plots the next 180 days so you can see clustering — on a wide screen as one lane per ticker, on a phone as a chronological list per month. Click any dot to jump straight to that ticker.
Click a card to open it: catalysts and the FDA stage stepper, market data (52-week range, analyst consensus, insider activity, cash position from the latest 8-K) and your own notes. On a phone that's split into two tabs so nothing gets cramped.
A date shown as Jul 29, 2026 came from a filing or registry as an actual date. A date shown as ≈ Q3 2026 with an ≈ est. tag is quarter- or month-level guidance — a company saying "data expected in the third quarter". It's placed on the calendar so you can plan around it, but it is not a fixed day. When the real date is announced later, BioLens upgrades the existing entry instead of leaving you with two.
Starting two weeks before a PDUFA date, BioLens watches news headlines and SEC filings for an approval, a Complete Response Letter or a delay, and tags the outcome automatically with a link to the source it used. The window opens early because the FDA regularly decides ahead of schedule under Priority Review or RTOR.
You can always set an outcome yourself, and your choice overrides the automatic one.
Always verify. Everything here is collected automatically from public sources. Dates get missed, misread or superseded. Before you act on anything, check the company's investor-relations page and the FDA calendar.
Open a ticker and fill in shares and average cost under "My analysis", or use the positions panel next to the portfolio total to fill in every name at once — the two stay in step, so editing either updates the other. Shares alone is enough to see a position's value; add a cost and you get profit and loss too.
The dashboard then shows total portfolio value, today's move and your all-time gain against cost basis, with a $ / € toggle for the headline totals. The chart button next to it plots that total over time, with your cost basis as a dashed break-even line and 1M / 3M / 6M / All ranges. It only records a point on days you actually open BioLens, so gaps mean days you didn't check, not flat performance.
The same panel holds a conviction rating (1–5 stars), your own price target, which appears alongside the analyst targets, and a free-text notes field that saves as you type — bull case, bear case, whatever you want to remember.
By default everything lives in the browser you're using, so your phone and your laptop each keep their own list. Creating a free account makes them share one — it's optional, and nothing changes if you skip it.
Your watchlist, positions, conviction ratings, price targets, notes and portfolio history. Your password is never stored as text — only a scrambled version that can't be turned back — which also means nobody, including us, can look it up for you.
There is no email reset. If you forget your password, the recovery code is the only way back in. Keep it somewhere safe — a password manager is ideal — and keep using ⋯ → Export data now and then as a plain backup.
Changes upload automatically: when you open the app, when you return to the tab, and a few seconds after you edit something. If two devices changed different things, both are kept; anything you deleted stays deleted. Offline you just keep working, and it uploads once you're back online. You can change your password any time while signed in.
The Coverage page follows a handful of biotech names properly, the way a research desk would. Each name opens with company coverage: what the company does, the pipeline, the bull case, the bear case, a rating and a price target — revised over time as things change, not locked to the day it was first written. After that it is kept current with short update notes around FDA decisions, data readouts and results — each of which can confirm or change the rating and the target.
Nothing is rewritten afterwards. Every note keeps the share price it was written at, so you can see how a call aged. Each note is one of three things: the company coverage itself, an update note that makes a call and gets an outcome later, or a development that simply records something that happened — no rating, no target, nothing to resolve, and it stays out of the track record. A name is marked under coverage while it is actively followed, and is closed off when the thesis plays out, coverage is dropped or the company is acquired — at which point its performance figure is locked to the closing price instead of drifting with the market. Written by Thomas Bouman; not financial advice.
If you track a name yourself, a 📝 appears on its card in the tracker whenever there's a thesis on it, and the published BioLens price target shows up next to the analyst targets with its potential upside — click it to read the reasoning behind the number. Any price target you set for yourself stays private to your own browser. These are personal notes, not recommendations.
Not financial advice. BioLens is a personal tracking tool. Nothing here is a recommendation to buy or sell anything, and biotech catalysts are genuinely risky events. Do your own research.